Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TDP2 | O95551 | 3/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | G6PD | P11413 | 2/20 | 0.30 |
| ▸ | USP14 | P54578 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12721697 | 0.99 | RORC (0.35) | RORCL3MBTL1KDM4EATMTDP2 | |
| SCHEMBL12721976 | 0.97 | RORC (0.40) | RORCL3MBTL1KDM4EATMTDP2 | |
| SCHEMBL12721724 | 0.95 | RORC (0.35) | RORCL3MBTL1TDP2USP2ALDH1A1 | |
| SCHEMBL12721741 | 0.95 | PTGDR2 (0.35) | RORCKDM4ETDP2USP14 | |
| SCHEMBL17463228 | 0.94 | KDM4E (0.41) | RORCL3MBTL1KDM4EATMTDP2 | |
| SCHEMBL13249739 | 0.93 | GABRA1 (0.34) | RORCABCG2USP14 | |
| SCHEMBL17463227 | 0.93 | KDM4E (0.40) | RORCL3MBTL1KDM4EATMTDP2 | |
| SCHEMBL13249700 | 0.92 | RORC (0.35) | RORCL3MBTL1KDM4EUSP2ALDH1A1 | |
| SCHEMBL13249709 | 0.92 | PGR (0.36) | RORCKDM4ETDP2USP14 | |
| SCHEMBL17463229 | 0.92 | L3MBTL1 (0.38) | RORCL3MBTL1KDM4EATMUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754349-B2 | Silanylamine-based compound and organic light-emitting device including organic layer including the silanylamine-based compound | SAMSUNG MOBILE DISPLAY CO., LTD. (KR) | 2010-07-13 | — | — | US | disclosed |
| US-20080171227-A1 | SILANYLAMINE-BASED COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANIC LAYER INCLUDING THE SILANYLAMINE-BASED COMPOUND | SAMSUNG SDI CO., LTD. (KR) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171227-A1 | SILANYLAMINE-BASED COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANIC LAYER INCLUDING THE SILANYLAMINE-BASED COMPOUND | ADRB2, ADRB1, ADRB3 | RORC 1290/4885L3MBTL1 841/4885KDM4E 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.